| Literature DB >> 34289827 |
Jesper Knoop1, Raymond W J G Ostelo2,3, Martin van der Esch4,5, Arjan de Zwart4, Kim L Bennell6, Marike van der Leeden4,7, Joost Dekker7.
Abstract
BACKGROUND: We recently developed a model of stratified exercise therapy, consisting of (i) a stratification algorithm allocating patients with knee osteoarthritis (OA) into one of the three subgroups ('high muscle strength subgroup' representing a post-traumatic phenotype, 'low muscle strength subgroup' representing an age-induced phenotype, and 'obesity subgroup' representing a metabolic phenotype) and (ii) subgroup-specific exercise therapy. In the present study, we aimed to test the construct validity of this algorithm.Entities:
Keywords: Construct validity; Exercise therapy; Knee osteoarthritis; Phenotypes; Stratification
Mesh:
Year: 2021 PMID: 34289827 PMCID: PMC8296670 DOI: 10.1186/s12891-021-04485-1
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Stratification algorithm. BMI = body mass index; 30s-CST = 30 s chair stand test; rep. = repetition
Overview of a-priori hypotheses (n = 63) and scores to accept these hypotheses
| RESEARCH QUESTION I: SIMILAR SUBGROUP PROPORTIONS | |
|---|---|
| Subgroup proportion in one cohort is similar to subgroup proportion in total sample | Deviation |
| AMS-OA [ | −10, + 10%1 |
| STABILO [ | −10, + 10%1 |
| NEXA [ | −10, + 10%1 |
| CBT [ | −10, + 10%1 |
| VIDEX (De Zwart AH, Dekker J, Roorda LD, van der Esch M, Lips P, van Schoor NM, et al.: High-intensity resistance training and vitamin D supplementation for knee osteoarthritis: a randomized controlled trial, Under review) vs. total sample | −10, + 10%1 |
| AMS-OA [ | − 10, + 10%1 |
| STABILO [ | −10, + 10%1 |
| NEXA [ | −10, + 10%1 |
| CBT [ | −10, + 10%1 |
| VIDEX (De Zwart AH, Dekker J, Roorda LD, van der Esch M, Lips P, van Schoor NM, et al.: High-intensity resistance training and vitamin D supplementation for knee osteoarthritis: a randomized controlled trial, Under review) vs. total sample | −10, + 10%1 |
| AMS-OA [ | − 10, + 10%1 |
| STABILO [ | −10, + 10%1 |
| NEXA [ | −10, + 10%1 |
| CBT [ | −10, + 10%1 |
| VIDEX (De Zwart AH, Dekker J, Roorda LD, van der Esch M, Lips P, van Schoor NM, et al.: High-intensity resistance training and vitamin D supplementation for knee osteoarthritis: a randomized controlled trial, Under review) vs. total sample | -10, + 10%1 |
| Higher age, compared to: | |
| ‘high muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| Lower muscle strength, compared to: | |
| ‘high muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| ‘ | |
| More history of knee surgery, compared to: | |
| ‘low muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| Higher muscle strength, compared to: | |
| ‘low muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| More males, compared to: | |
| ‘low muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| Younger age, compared to: | |
| ‘low muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| Higher K/L grade, compared to: | |
| ‘low muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| Less comorbidities, compared to: | |
| ‘low muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| Less severe knee pain, compared to: | |
| ‘low muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| Less impaired physical function, compared to: | |
| ‘low muscle strength subgroup’ | |
| ‘obesity subgroup’ | |
| Higher BMI, compared to: | |
| ‘high muscle strength subgroup’ | |
| ‘low muscle strength subgroup’ | |
| More comorbidities, compared to: | |
| ‘high muscle strength subgroup’ | |
| ‘low muscle strength subgroup’ | |
| Lower muscle strength, compared to: | |
| ‘high muscle strength subgroup’ | |
| ‘low muscle strength subgroup’ | |
| More severe knee pain, compared to: | |
| ‘high muscle strength subgroup’ | |
| ‘low muscle strength subgroup’ | |
| More severe impaired physical function, compared to: | |
| ‘high muscle strength subgroup’ | |
| ‘low muscle strength subgroup’ | |
| Large effect size on knee pain | 0.8 ± 0.2 |
| Majority with MIC on knee pain | > 67% |
| Large effect size on physical function | 0.8 ± 0.2 |
| Majority with MIC on physical function | > 67% |
| Large effect size on muscle strength | 0.8 ± 0.2 |
| Majority with MIC on muscle strength | < 67% |
| Medium effect size on knee pain | 0.5 ± 0.2 |
| Half with MIC on knee pain | 33–67% |
| Medium effect size on physical function | 0.5 ± 0.2 |
| Half with MIC on physical function | 33–67% |
| Medium effect size on muscle strength | 0.5 ± 0.2 |
| Half with MIC on muscle strength | 33–67% |
| Small effect size on knee pain | 0.2 ± 0.2 |
| Minority with MIC on knee pain | < 33% |
| Small effect size on physical function | 0.2 ± 0.2 |
| Minority with MIC on physical function | < 33% |
| Small effect size on muscle strength | 0.2 ± 0.2 |
| Minority with MIC on muscle strength | < 33% |
MIC = minimal important change; 1 difference in subgroup proportion (%)in one cohort compared to subgroup proportion in total sample; 2 p-value for differences between subgroups; 3 isokinetic knee extensor strength measure as outcome; 4 30-s chair stand test as outcome; *significant finding in the opposite direction as expected, therefore hypothesis not accepted
Characteristics in each cohort
| AMS-OA (5) | STABILO (17) | NEXA (18) | CBT (19) | VIDEX (20) | Total sample | |
|---|---|---|---|---|---|---|
| N | 553 | 159 | 100 | 222 | 177 | 1211 |
| N with exercise therapy | 0 | 159 | 100 | 148 | 177 | 584 |
| Gender (female), n (%) | 397 (72%) | 97 (61%) | 52 (52%) | 133 (60%) | 107 (61%) | 786 (65%) |
| Age (years), mean ± SD | 62.9 ± 9.4 | 61.9 ± 7.1 | 62.4 ± 7.3 | 63.4 ± 8.0 | 67.6 ± 5.8 | 63.5 ± 8.4 |
| Radiographic severity: | ||||||
| K&L grade 0/1, n (%) | 185 (38%) | 49 (31%) | 0 (0%) | 0 (0%) | 61 (35%) | 296 (26%) |
| K&L grade 2, n (%) | 125 (25%) | 44 (28%) | 22 (22%) | 90 (41%) | 59 (33%) | 340 (30%) |
| K&L grade 3, n (%) | 97 (20%) | 45 (28%) | 43 (43%) | 63 (28%) | 29 (16%) | 277 (24%) |
| K&L grade 4, n (%) | 86 (17%) | 21 (13%) | 35 (35%) | 69 (31%) | 28 (16%) | 239 (21%) |
| History of knee surgery, n (%) | n/a | n/a | 49 (49%) | 91 (41%) | n/a | 140 (44%) |
| Nr. of comorbidities (CIRS ≥2): | ||||||
| 0, n (%) | 259 (48%) | n/a | n/a | n/a | 131 (76%) | 390 (55%) |
| 1, n (%) | 152 (28%) | 42 (24%) | 194 (27%) | |||
| 2, n [ | 73 (14%) | 0 (0%) | 73 (10%) | |||
| ≥ 3, n (%) | 58 (11%) | 0 (0%) | 58 (8%) | |||
| Knee pain (0–10, NRS/VAS), mean ± SD | 5.8 ± 2.4 | 5.0 ± 2.1 | 5.4 ± 1.5 | 5.9 ± 1.3 | 4.7 ± 2.2 | 5.5 ± 2.1 |
| Physical function (0–100, WOMAC), mean ± SD | 47.1 ± 20.5 | 38.5 ± 18.0 | 40.0 ± 14.1 | 51.4 ± 10.7 | 30.7 ± 19.3 | 43.7 ± 19.2 |
| Body mass index (kg/m2), mean ± SD | 31.9 ± 6.7 | 29.0 ± 4.6 | 29.6 ± 4.1 | 31.1 ± 6.1 | 28.2 ± 4.4 | 30.6 ± 6.0 |
| Quadriceps strength (Nm/kg), mean ± SD | 0.84 ± 0.53 | 0.98 ± 0.51 | n/a | n/a | 1.12 ± 0.49 | 0.92 ± 0.53 |
| 30s-CST (repetitions), mean ± SD | n/a | n/a | 10.7 ± 2.6 | 8.7 ± 2.7 | n/a | 9.3 ± 2.8 |
K/L = Kellgren & Lawrence; CIRS = Cumulative Illness Rating Score; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; NRS = Numeric Rating Scale; VAS = Visual Analogue Scale; 30s-CST = 30 s chair stand test; n/a = not applicable (not assessed)
Comparison of subgroup proportions across cohorts (research question 1; findings resulting in accepted hypotheses in bold)
| Low muscle strength subgroup | High muscle strength subgroup | Obesity subgroup | ||||
|---|---|---|---|---|---|---|
| N (%) | Difference with total sample | N (%) | Difference with total sample | N (%) | Difference with total sample | |
| 167 (30%) | 79 (14%) | 307 (56%) | ||||
| 60 (38%) | 37 (23%) | 62 (39%) | ||||
| 33 (33%) | 23 (23%) | 44 (44%) | ||||
| 94 (42%) | 16 (7%) | −11% | 112 (51%) | |||
| 67 (38%) | 58 (33%) | + 15% | 52 (29%) | −19% | ||
Comparison of observed subgroup characteristics that are in line with proposed underlying phenotype with other subgroups (research question 2; findings resulting in accepted hypotheses in bold)
| Low muscle strength subgroup (L) | High muscle strength subgroup (H) | Obesity subgroup (O) | Difference between L and H | Difference between L and O | Difference between H and O | |
|---|---|---|---|---|---|---|
| Gender (female), n (%) | 310 (74%) | 88 (41%) | 388 (67%) | |||
| Age (years), mean ± SD | 65.2 ± 8.4 | 62.3 ± 8.6 | 62.7 ± 8.3 | |||
| Radiographic severity: | ||||||
| K&L grade 0/1, n (%) | 95 (24%) | 72 (35%) | 128 (24%) | |||
| K&L grade 2, n (%) | 131 (33%) | 64 (31%) | 145 (27%) | |||
| K&L grade 3, n (%) | 92 (23%) | 48 (23%) | 137 (25%) | |||
| K&L grade 4, n (%) | 83 (21%) | 42 (12%) | 132 (24%) | |||
| Knee surgery, n (%) | 51 (40%) | 24 (63%) | 65 (42%) | |||
| Nr. of comorbidities: | ||||||
| 0, n (%) | 142 (62%) | 97 (71%) | 151 (43%) | |||
| 1, n (%) | 61 (15%) | 28 (21%) | 105 (30%) | |||
| 2. n (%) | 13 (3%) | 8 (6%) | 52 (15%) | |||
| ≥ 3, n (%) | 14 (3) | 3 (2%) | 41 (12) | |||
| Knee pain (0–10), mean ± SD | 5.6 ± 2.0 | 4.7 ± 2.2 | 5.8 ± 2.1 | |||
| Physical function (WOMAC, 0–68), mean ± SD | 43.6 ± 17.3 | 30.6 ± 18.2 | 48.7 ± 18.6 | |||
| Body mass index (kg/m2), mean ± SD | 26.4 ± 2.5 | 25.8 ± 2.4 | 35.5 ± 5.0 | |||
| Quad. strength (Nm/kg), mean ± SD | 0.71 ± 0.31 | 1.62 ± 0.32 | 0.78 ± 0.48 | |||
| 30s-CST (repetitions), mean ± SD | 8.5 ± 2.3 | 13.2 ± 1.2 | 9.0 ± 2.7 | |||
K/L = Kellgren & Lawrence; CIRS = Cumulative Illness Rating Score; 30s-CST = 30 s chair stand test
* significant finding in the opposite direction as expected, therefore hypothesis not accepted
Comparison of observed effects of usual exercise therapy for each subgroup with hypothesized effects (research question 3; findings resulting in accepted hypotheses in bold)
| Low muscle strength subgroup | Obesity subgroup | High muscle strength subgroup | ||||
|---|---|---|---|---|---|---|
| Observed | Hypothesized | Observed | Hypothesized | Observed | Hypothesized | |
| Effect size1 | 1.10 | 0.5 ± 0.2 | 0.82 | 0.2 ± 0.2 | ||
| % persons with MIC2 | 72% | 33–67% | 66% | < 33% | ||
| Effect size1 | 0.78 | 0.5 ± 0.2 | 0.49 | 0.2 ± 0.2 | ||
| % persons with MIC3 | 76% | 33–67% | 76% | < 33% | ||
| Effect size1 | ||||||
| % persons with MIC4,5 | 49% / 31% | > 67% | 32% / 28% | 33–67% | 7% / 9% | < 33% |
MIC = minimal important change. 1 Effect size (within-group) = change score within group / standard deviation at baseline; 2 MIC defined as improvement on NRS/VAS pain (0–100) ≥ 15% and/or ≥ 1 point [25]; 3MIC defined as improvement on WOMAC physical function (0–100) ≥ 12% [26]; 4 MIC defined as improvement on quadriceps strength ≥30% [27]; 5 MIC defined as improvement on 30s-CST ≥ 2 repetitions [28]